Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia

Round 1

Reviewer 1 Report

The manuscript presented here by Chi and Minami is a brief review of the status of newly developed treatment options for AML.The authors describe the status of clinical trials of new inhibitory drugs against FLT3-ITD, IDH1 and IDH2, BCL2, MLL rearrangements, NPM1, NUP98, SYK, TP53, CD47 and RAS. While the authors do not go into depth in any of these paragraphs, overall this is a short, well done review of this topic that summarizes well the literature of 120 references. Overall, one cannot expect this article to explain overwhelming new associations, it is really just a summary of clinical activities. Because of the need to review the spellings of genes and proteins throughout the manuscript, I recommend acceptance after a minor revision. 

Page 5 Figure Legend line 3, Bcl-2 homology 3-only proteins, Bcl-2-associated....
Page 7 paragraph 2 line 8, MPM1-mutated leukemia.
Page 7 paragraph 3 line 5, meis1
Page 9 line 11, ant-leukemia effect

Author Response

Thank you so much for the important suggestion below:

Page 5 Figure Legend line 3, Bcl-2 homology 3-only proteins, Bcl-2-associated....
Page 7 paragraph 2 line 8, MPM1-mutated leukemia.
Page 7 paragraph 3 line 5, meis1
Page 9 line 11, ant-leukemia effect

We have corrected these points in our revised manuscript.

Reviewer 2 Report

Chi and Minami have proposed a comprehensive overview of target treatments in AML. I find this work complete and very useful.
My only suggestion is to double-check and correct some typos and spelling errors.

Author Response

Thank you so  much for the precious suggestion:

>My only suggestion is to double-check and correct some typos and spelling errors.

We have carefully done the check, again.